Over 7 Million Americans Need Advanced Migraine Treatment.
Only 575,000 Are Getting It.

For the 7–10 million patients who've failed other therapies and are clinically appropriate for CGRP/gepant medications, the problem isn't the drugs — it's the gauntlet of administrative, financial, and systemic barriers standing between them and relief.

Roughly 1 in 14 clinically appropriate patients is on continuous CGRP/gepant therapy.

The Compounding Cascade

Each stage of the treatment journey loses patients. The barriers compound — and the system's most modifiable failures sit right in the middle.

Total with migraine
~39,000,000
Diagnosed
~24,000,000
↓ ~38% lost Awareness, stigma, access
Prescribed a CGRP/gepant
~3–4M
↓ ~57–60% lost Prescriber inertia, specialist shortage
PA approved
~2.4–3.2M
↓ ~20% lost PA friction, denials
Filled at pharmacy
~1.4–2.2M
↓ ~30–40% lost Cost shock, abandonment
On therapy at 12 months
~575K
↓ ~45% lost Cost, non-response, PA renewal gaps
1 in 14

Of the 7–10 million Americans clinically appropriate for CGRP/gepant therapy — patients who've failed other treatments — only about 575,000 are on continuous therapy at any given time.

The Diagnosis Gap, Mapped

15.3 million Americans with migraine remain undiagnosed. Geographic disparities in care access leave entire communities without treatment.

Interactive map: Estimated undiagnosed migraine patients by ZIP code

Undiagnosed migraine
Of ~39 million Americans with migraine, approximately 15.3 million have never received a diagnosis.
American Migraine Foundation
Specialist shortage
Only 564 UCNS-accredited headache specialists serve ~39 million patients. The field needs at least 3,700.
Headache journal; AHS
Wait times
Average 3.7 months for a first specialist visit — up to 14 months in some areas.
Kainth et al., Neurology & Therapy (2020)
Primary care knowledge gap
Medical school devotes roughly 3 hours to headache education, yet 52.8% of migraine encounters happen in primary care.
AHS; Medscape/AHS 2024
Stigma and minimization
Patients don't seek care and providers dismiss symptoms as "just headaches."
AHS; American Migraine Foundation
Prescriber inertia
PCPs comfortable with triptans rarely escalate to CGRPs even when clinically indicated.
AHS clinical guidance
Step therapy requirements
96% of managed care organizations require trial and failure of at least one non-CGRP preventive before approval. 56% require two or more.
AJMC MCO analysis (2025)
Outdated insurer policies
Insurers still require step therapy despite the AHS 2024 position statement recommending CGRPs as first-line treatment.
AHS Position Statement (2024)
No standardization across plans
Every health plan has its own prior authorization criteria — no two are alike.
AJMC; Dr. Maria Lopes, MD
Documentation errors
Incomplete or incorrect PA submissions are a leading cause of denial. Staff frequently skip unanswered questions.
Dr. Vera Gibb, AMD (2023)
Wrong diagnosis codes
Overly specific ICD codes like "ocular migraine" trigger denials when they aren't in payer dropdown menus.
Dr. Vera Gibb, AMD (2023)
PA required for nearly all CGRPs
96% of managed care organizations require prior authorization for CGRP antagonists.
AJMC (2025)
Processing delays
Average 2–5 business days for PA processing; specialty drugs often longer.
AMA Prior Auth Survey
Denial on first submission
Significant initial denial rates, especially for incomplete submissions.
AJMC; Dr. Vera Gibb
7% of all Rx claims rejected by PA
Of those rejections, 37% are abandoned entirely — the prescription is never filled.
Medication Access Report (2020)
Appeal complexity
Multi-step appeal processes cause many providers and patients to give up.
American Migraine Foundation
Renewal friction
PA approvals typically expire every 6–12 months, requiring full re-documentation.
FEP Blue PA policies (2024)
Specialist-only restrictions
Some plans require CGRP prescriptions from headache specialists — and some states don't have any.
Shoshana Lipson, AJMC
Sticker shock
CGRP wholesale cost runs ~$1,200/month ($14,400/year). Without copay assistance, patients face $500–$700+/month out of pocket.
AbbVie WAC data (Jan 2026)
Cost-driven abandonment
Cost sharing above $100 is associated with abandonment rates up to 75% for specialty drugs.
JMCP systematic review (2023)
Copay assistance unawareness
Manufacturer programs can reduce costs to $0–$10/month, but many patients never learn they exist.
Assoc. of Migraine Disorders (2025)
Medicare/Medicaid exclusion
Government-insured patients are ineligible for manufacturer copay assistance programs.
Federal law; PAN Foundation
Formulary tier placement
CGRPs are typically placed on specialty tiers (Tier 4+) with 25–33% coinsurance instead of flat copays.
CMS formulary data; DLA Piper (2026)
45% discontinue within 12 months
Pooled 12-month CGRP monoclonal antibody adherence is ~55%. Oral preventives are even worse at ~14%.
Cureus review, 11 studies (2025)
PA expiration gaps
Lapsed prior authorizations create gaps in medication supply. Many patients never restart.
FEP Blue; provider reports
Injection aversion
Self-injection barriers drive some patients away from monoclonal antibodies, though oral gepants are growing 61% year-over-year.
Market data (Qulipta trends)
Non-response to first CGRP
~25% of patients don't achieve a clinically meaningful response to the first CGRP they try.
Burgalassi et al., Cephalalgia (2024)
Loss to follow-up
Patients doing well cancel appointments. Without a provider visit, PA renewals lapse.
Dr. Vera Gibb, AMD

Sources

AJMC · American Headache Society · American Migraine Foundation · AMA · Association of Migraine Disorders · CMS · Cureus · DLA Piper · FEP Blue · Journal of Headache and Pain · JMCP · Kainth et al. (Neurology & Therapy) · Medscape · NeurologyLive · PAN Foundation · Manufacturer earnings reports (Pfizer, AbbVie, Eli Lilly, Amgen). All figures represent best available estimates from published literature and public data. Last updated February 2026.

This Is the Problem We're Solving

The Headache Vault automates the prior authorization process so clinicians can focus on patients — not paperwork.

Try the PA Engine Beta →